Newsletter Tool

Featured Story

J&J’s next COVID-19 vaccine challenge? Hurdling the ‘66%’ perception to win over a vaccine-hesitant public

By Beth Snyder Bulik

As Johnson & Johnson rolls out its COVID-19 vaccine under a new FDA emergency authorization, the pharma faces a communications hurdle. How will it counter the wide and spreading discussions about the shot's overall effectiveness of 66% when compared to Pfizer and Moderna's 90%-plus effectiveness rates?

These are the health earmarks in the $1.9T relief package that passed the House

By Robert King

The House passed a $1.9 trillion COVID-19 relief package that includes several healthcare provisions such as a temporary boost to ACA subsidies and expanding Medicaid coverage.

AstraZeneca cashes in on Moderna, collecting $1B-plus as COVID-19 added rocket fuel to the mRNA biotech's shares

By Angus Liu

Another investor has benefited big time—to the tune of $1 billion—from Moderna's surging stock price during its work on COVID-19. AstraZeneca cashed out its entire 7.7% stake in the mRNA specialist last year, the British pharma said in its annual report, collecting a big return on its $290 million investment.

Mayo Clinic's revenue slightly increases in 2020 despite financial hit from pandemic

By Robert King

Mayo Clinic posted a 1.5% increase in revenue for 2020 as the hospital system recovered from patient volume declines caused by the COVID-19 pandemic.

Moffitt Cancer Center's CEO is working to cure cancer amid a pandemic—while playing in a rock band

By Tina Reed

Moffitt Cancer Center CEO Patrick Hwu spoke with Fierce Healthcare about everything from running a cancer center amid a pandemic, researchers balancing conflicts to trying to have a life while saving lives.

Hologic further expands diagnostics reach with $159M Diagenode tuck-in buy

By Conor Hale

After seeing diagnostics revenues increase by 450% last quarter to meet global COVID-19 demands, Hologic continues to reinvest the proceeds into its testing divisions, now with its third multimillion-dollar acquisition of the year so far.

COVID-19 tracker: J&J works to boost vaccine confidence and bolster supply; AstraZeneca's big score

By Kevin Dunleavy,Fraiser Kansteiner,Eric Sagonowsky,Angus Liu,Conor Hale

Johnson & Johnson and health officials are trying to boost public confidence in J&J's COVID-19 vaccine. J&J is "leaving no stone unturned" in bolstering vaccine production and supply, its CEO said. AstraZeneca scored roughly $1 billion after selling its equity stake in Moderna. Plus more.

COVID-19 Tracker